1
|
Ren H, Maloney KM, Basu K, Di Maso MJ, Humphrey GR, Peng F, Desmond R, Otte DAL, Alwedi E, Liu W, Zhang SW, Song S, Arvary RA, Zompa MA, Lehnherr D, Martin GE, Chang HYD, Mohan AE, Guzman FJ, Jellett L, Lee AY, Spencer G, Fisher ES, Naber JR, Gao H, Lohani S, Ruck RT, Campeau LC. Development of a Green and Sustainable Manufacturing Process for Gefapixant Citrate (MK-7264) Part 1: Introduction and Process Overview. Org Process Res Dev 2020. [DOI: 10.1021/acs.oprd.0c00248] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Hong Ren
- Department of Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Kevin M. Maloney
- Department of Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Kallol Basu
- Department of Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Michael J. Di Maso
- Department of Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Guy R. Humphrey
- Department of Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Feng Peng
- Department of Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Richard Desmond
- Department of Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Douglas A. L. Otte
- Department of Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Embarek Alwedi
- Department of Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Wenjun Liu
- Department of Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Si-Wei Zhang
- Department of Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Siqing Song
- Department of Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Rebecca A. Arvary
- Department of Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Michael A. Zompa
- Department of Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Dan Lehnherr
- Department of Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Gary E. Martin
- Department of Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Hsieh Yao D. Chang
- Department of Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Anne E. Mohan
- Department of Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Francisco J. Guzman
- Department of Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Lisa Jellett
- Department of Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Alfred Y. Lee
- Department of Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Glenn Spencer
- Department of Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Elizabeth S. Fisher
- Department of Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - John R. Naber
- Department of Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Hong Gao
- Department of Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Sachin Lohani
- Department of Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Rebecca T. Ruck
- Department of Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Louis-Charles Campeau
- Department of Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| |
Collapse
|
2
|
Cai Y, Chen T, Zhu H, Zou H. Design, Synthesis and Antitumor Assessment of Phenylureas Bearing 5-Fluoroindolin-2-one Moiety. Med Chem 2020; 16:958-968. [PMID: 32026784 DOI: 10.2174/1573406416666200206123319] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2019] [Revised: 11/24/2019] [Accepted: 12/23/2019] [Indexed: 11/22/2022]
Abstract
BACKGROUND The development of novel antineoplastic agents remains highly desirable. OBJECTIVE This study focuses on the design, synthesis, and antitumor evaluation of phenyl ureas bearing 5-fluoroindolin-2-one moiety. METHODS Three sets of phenylureas were designed and synthesized and their antiproliferative ability was measured against four human carcinoma cell lines (Hela, Eca-109, A549, and MCF-7) via MTT assay. In vivo anticancer activity was further evaluated in xenograft models of human breast cancer (MCF-7). RESULTS A total of twenty-one new compounds were synthesized and characterized by means of 1H and 13C NMR as well as HR-MS. Three sets of compounds (1a‒1c, 2a‒2c, and 3a‒3c) were initially constructed, and preliminary antiproliferative activities of these molecules were evaluated against Hela, Eca-109, A549 and MCF-7, highlighting the meta-substituted phenylureas (1a‒1c) as the most cytotoxic set. A series of meta-substituted phenylureas derivatives (1d‒1o) were then designed and synthesized for structure-activity relationship study. Most of the new compounds showed desirable cytotoxicity, among which compound 1g exhibited the most remarkable cytotoxic effects against the tested human cancer cells with IC50 values ranging from 1.47 to 6.79 μM. Further studies showed that compound 1g suppressed tumor growth in human breast cancer (MCF- 7) xenograft models without affecting the body weight of its recipients. CONCLUSION In this study, twenty-one new compounds, containing the privileged structures of phenylurea and 5-fluoroindolin-2-one, were designed and synthesized. Subsequent structureactivity studies showed that 1g was the most bioactive antitumor agent among all tested compounds, hence a potentially promising lead compound once given further optimization.
Collapse
Affiliation(s)
- Yunrui Cai
- College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, P.R. China
| | - Tong Chen
- College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, P.R. China
| | - Huajian Zhu
- College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, P.R. China,Zhejiang University City College, Hangzhou, 310015 Zhejiang, P.R. China
| | - Hongbin Zou
- College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, P.R. China
| |
Collapse
|
4
|
Gómez-Palomino A, Cornella J. Selective Late-Stage Sulfonyl Chloride Formation from Sulfonamides Enabled by Pyry-BF 4. Angew Chem Int Ed Engl 2019; 58:18235-18239. [PMID: 31595619 PMCID: PMC6916363 DOI: 10.1002/anie.201910895] [Citation(s) in RCA: 46] [Impact Index Per Article: 9.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2019] [Revised: 09/24/2019] [Indexed: 01/08/2023]
Abstract
Reported here is a simple and practical functionalization of primary sulfonamides, by means of a pyrylium salt (Pyry‐BF4), with nucleophiles. This simple reagent activates the poorly nucleophilic NH2 group in a sulfonamide, enabling the formation of one of the best electrophiles in organic synthesis: a sulfonyl chloride. Because of the variety of primary sulfonamides in pharmaceutical contexts, special attention has been focused on the direct conversion of densely functionalized primary sulfonamides by a late‐stage formation of the corresponding sulfonyl chloride. A variety of nucleophiles could be engaged in this transformation, thus permitting the synthesis of complex sulfonamides, sulfonates, sulfides, sulfonyl fluorides, and sulfonic acids. The mild reaction conditions and the high selectivity of Pyry‐BF4 towards NH2 groups permit the formation of sulfonyl chlorides in a late‐stage fashion, tolerating a preponderance of sensitive functionalities.
Collapse
Affiliation(s)
- Alejandro Gómez-Palomino
- Max-Planck-Institut für Kohlenforschung, Kaiser-Wilhelm-Platz 1, 45470, Mülheim an der Ruhr, Germany
| | - Josep Cornella
- Max-Planck-Institut für Kohlenforschung, Kaiser-Wilhelm-Platz 1, 45470, Mülheim an der Ruhr, Germany
| |
Collapse
|
8
|
Wu M, Dai G, Yao J, Hoyt S, Wang L, Mu J. Potentiation of insulin-mediated glucose lowering without elevated hypoglycemia risk by a small molecule insulin receptor modulator. PLoS One 2015; 10:e0122012. [PMID: 25799496 PMCID: PMC4370409 DOI: 10.1371/journal.pone.0122012] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2014] [Accepted: 02/10/2015] [Indexed: 12/30/2022] Open
Abstract
Insulin resistance is the key feature of type 2 diabetes and is manifested as attenuated insulin receptor (IR) signaling in response to same levels of insulin binding. Several small molecule IR activators have been identified and reported to exhibit insulin sensitization properties. One of these molecules, TLK19781 (Cmpd1), was investigated to examine its IR sensitizing action in vivo. Our data demonstrate that Cmpd1, at doses that produced minimal efficacy in the absence of insulin, potentiated insulin action during an OGTT in non-diabetic mice and enhanced insulin-mediated glucose lowering in diabetic mice. Interestingly, different from insulin alone, Cmpd1 combined with insulin showed enhanced efficacy and duration of action without increased hypoglycemia. To explore the mechanism underlying the apparent glucose dependent efficacy, tissue insulin signaling was compared in healthy and diabetic mice. Cmpd1 enhanced insulin’s effects on IR phosphorylation in both healthy and diabetic mice. In contrast, the compound potentiated insulin’s effects on Akt phosphorylation in diabetic but not in non-diabetic mice. These differential effects on signaling corresponding to glucose levels could be part of the mechanism for reduced hypoglycemia risk. The in vivo efficacy of Cmpd1 is specific and dependent on IR expression. Results from these studies support the idea of targeting IR for insulin sensitization, which carries low hypoglycemia risk by standalone treatment and could improve the effectiveness of insulin therapies.
Collapse
Affiliation(s)
- Margaret Wu
- Early Development and Discovery Sciences, Merck Research Laboratories, Merck Sharp & Dohme Corp., Whitehouse Station, NJ 08889, United States of America
| | - Ge Dai
- Early Development and Discovery Sciences, Merck Research Laboratories, Merck Sharp & Dohme Corp., Whitehouse Station, NJ 08889, United States of America
| | - Jun Yao
- Early Development and Discovery Sciences, Merck Research Laboratories, Merck Sharp & Dohme Corp., Whitehouse Station, NJ 08889, United States of America
| | - Scott Hoyt
- Early Development and Discovery Sciences, Merck Research Laboratories, Merck Sharp & Dohme Corp., Whitehouse Station, NJ 08889, United States of America
| | - Liangsu Wang
- Early Development and Discovery Sciences, Merck Research Laboratories, Merck Sharp & Dohme Corp., Whitehouse Station, NJ 08889, United States of America
| | - James Mu
- Early Development and Discovery Sciences, Merck Research Laboratories, Merck Sharp & Dohme Corp., Whitehouse Station, NJ 08889, United States of America
- * E-mail:
| |
Collapse
|
10
|
Fontán N, García-Domínguez P, Álvarez R, de Lera ÁR. Novel symmetrical ureas as modulators of protein arginine methyl transferases. Bioorg Med Chem 2013; 21:2056-67. [PMID: 23395110 DOI: 10.1016/j.bmc.2013.01.017] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2012] [Revised: 01/02/2013] [Accepted: 01/06/2013] [Indexed: 10/27/2022]
Abstract
Methylation of histone arginine residues is an epigenetic mark related to gene expression that is implicated in a variety of biological processes and can be reversed by small-molecule modulators of protein arginine methyltransferases (PRMTs). A series of symmetrical ureas, designed as analogues of the known PRMT1 inhibitor AMI-1 have been synthesized using Pd-catalyzed Ar-N amide bond formation processes or carbonylation reactions as key steps. Their inhibitory profile has been characterized. The enzymatic assays showed a weak effect on PRMT1 and PRMT5 activity for most of the compounds. The acyclic urea that exhibited the strongest effect on the inhibition of the PRMT1 activity also showed the greatest effect on the expression of some androgen receptor target genes (TMPRSS2 and FKBP5), which may be related with its enzymatic activity. Surprisingly, AMI-1 behaved as an activator of PRMT5 activity, a result not reported so far.
Collapse
Affiliation(s)
- Noelia Fontán
- Departamento de Química Orgánica, Facultade de Química, Universidade de Vigo, 36310 Vigo, Spain
| | | | | | | |
Collapse
|